DEA Stacks Rescheduling Hearing With Reform Opponents Only

The Drug Enforcement Administration has invited only opponents of cannabis rescheduling to participate in its upcoming hearing on marijuana's federal classification, creating a one-sided forum that threatens to derail reform momentum. The agency began notifying selected participants Thursday, revealing a participant list that excludes proponents of moving cannabis from Schedule I to Schedule III.

This development represents a critical juncture for the cannabis industry, which has rallied around rescheduling as a pathway to reduced tax burdens and expanded banking access. Multi-state operators like Curaleaf Holdings (CURA), Green Thumb Industries (GTII), and Trulieve Cannabis (TCNNF) face effective tax rates exceeding 70% under Section 280E, which prohibits standard business deductions for Schedule I substances. Rescheduling could unlock hundreds of millions in tax savings across the sector.

The DEA's participant selection strategy suggests federal agencies remain resistant to cannabis reform despite growing state-level legalization and industry maturation. This resistance comes as the sector struggles with oversupply, compressed margins, and limited interstate commerce. Major operators have consolidated operations and reduced headcount while waiting for federal clarity that would enable cross-border expansion and institutional investment.

Investor sentiment around federal reform has fluctuated dramatically over the past two years, with cannabis stocks experiencing volatile swings based on regulatory developments. The exclusion of reform advocates from the hearing could signal prolonged federal prohibition, potentially extending the industry's regulatory limbo and maintaining barriers to traditional financing and banking services.

The hearing's composition raises questions about the administration's commitment to evidence-based drug policy and could influence congressional appetite for comprehensive cannabis legislation. Without balanced representation, the proceeding may lack the scientific and economic testimony that has supported rescheduling arguments, potentially setting back reform efforts that the industry views as essential for long-term viability and growth.